SNGX: Phase 3 FLASH2 Trial Enrolls 50th Patient Interim Analysis in 2Q26
On November 19, 2025, Soligenix, Inc. (SNGX) announced that 50 patients are now enrolled in the ongoing Phase 3 FLASH2 Trial of HyBryte for the...
169 Views
SNGX: DMC Reports No Safety Signals for Ongoing Phase 3 Trial in CTCL Blinded Interim Efficacy Analysis in 1H26
On November 7, 2025, Soligenix, Inc. (SNGX) announced financial results for the third quarter of 2025 and provided a business update. Recently,...
191 Views
SNGX: Public Offering Raises 7.5 Million Expands European Medical Advisory Board
On September 29, 2025, Soligenix, Inc. (SNGX) announced the closing of a previously announced public offering that resulted in gross proceeds of...
298 Views
SNGX: Dusquetide (SGX945) Granted Orphan Drug Designation for Behcet's Disease
On August 14, 2025, Soligenix, Inc. (SNGX) announced financial results for the second quarter of 2025 and provided a business update. Following...
173 Views
SNGX: Encouraging Results from Phase 2a Study of SGX945 in Behcet's Disease
On July 31, 2025, Soligenix, Inc. (SNGX) announced encouraging results from the Phase 2a clinical trial of SGX-945 (dusquetide) for the treatment...
197 Views